Introduction {#s1}
============

Sepsis, a syndrome of clinical and biochemical abnormalities induced by infection, remains a major public health issue, still with high mortality rates. The incidence of sepsis is increasing worldwide, as several populations with underlying comorbidities are affected \[[@R01], [@R02]\]. In particular, patients with diabetes are suffering from the highest infection rates.

Several mechanisms are associated with the increased susceptibility of the diabetic patients when infected. Excessive innate and adaptive immune system changes that the human body cannot overcome are taking place as part of the combined underlying chronic immune suppression of diabetes and the sepsis-induced immune alterations \[[@R03]\].

The role of neutrophils is crucial for the containment and the eradication of the micro-organisms. These cells are part of the innate immune system, producing pro- and anti-inflammatory cytokines and growth factors, and also are involved in the regulation of the inflammatory response \[[@R04]\]. Diabetes is characterized by some specific deficits in the cell migration to the inflammatory sites, alterations in phagocytosis and release of lytic proteases, production of reactive oxygen species (ROS), altered apoptosis and an excessive release of tumor necrosis factor (TNF), interleukin (IL)-1β, and IL-8 after stimulation by lipopolysaccharide (LPS). The last is related to cell death and increased susceptibility to micro-organisms \[[@R05], [@R06]\]. Aims of the study are to investigate the phagocytic activity and the expression of antigens HLA-DR and CD64 on monocytes and neutrophils in diabetic patients suffering from sepsis and evaluate their prognostic validity.

Materials and Methods {#s2}
=====================

The study was conducted in the Internal Medicine Department of the University Hospital of Patras, Greece, during the period from December 2016 to December 2017. All enrolled patients gave consent for participating in the study and the University Hospital Ethics Committee approved the protocol. During the study period, 51 diabetics (one with type 1 diabetes and 50 with type 2 diabetes) with sepsis, 22 women and 29 men, were enrolled. Fourteen of them had excellent glycemic control (HbA1c ≤ 7 or HbA1c ≤ 53 mmol/mol), while the rest had moderate (7 ≤ HbA1c ≤ 8.5 or 53 \< HbA1c ≤ 69.40 mmol/mol) or bad glycemic control (HbA1c ≥ 8.5 or HbA1c \> 69.40 mmol/mol). With regards to treatment of diabetes, 16 patients were on insulin, 25 were on oral medication (metformin, sulfonylurea, pioglitazone, dipeptidyl peptidase-4 (DPP-4) inhibitors), two were on a combined treatment and eight did not follow any treatment. Three of our patients came along with diabetic ketoacidosis as a result of their underlying infection. Eleven patients had been diagnosed with diabetes mellitus (DM) in the past 5 years, whereas 24 had diabetes for 10 years or more. As far as diabetic complications were concerned, four patients suffered from peripheral angiopathy and five from diabetic nephropathy. Regarding the existence of other chronic diseases, 28 patients with diabetes had arterial hypertension, hyperlipidemia was present in 12, 12 patients had ischemic heart disease, six had congestive heart failure, eight had atrial fibrillation, nine had chronic obstructive pulmonary disease (COPD), four were obese, and eight had a history of stroke. Exclusion criteria for participating in the study were known renal, hepatic or any autoimmune disease, treatment with steroids or any immuno-effective agent, diabetics with known white blood cells abnormalities, and those without complete data during the study period.

The definition of sepsis was based on the documented positive culture infection or presumed infection accompanied by two or more of the criteria of systemic inflammatory response syndrome (SIRS). The diagnostic workup consisted of clinical assessment in combination to evaluation of inflammatory markers (white blood count, C-reactive protein), biochemical panel, blood, urine or any other suspicious site specimen cultures, and specific diagnostic procedures when necessary to identify the cause of sepsis (e.g. computed tomography, magnetic resonance imaging).

HLA-DR, CD64 and phagocytosis measurements {#s2a}
------------------------------------------

In order to measure the phagocytic activity of neutrophils and monocytes, 5 mL of peripheral blood was obtained in heparinized tubes. The determination of HLA-DR and CD64 expression on neutrophils and monocytes was operated through dual-colour cytometry flow analysis. More specific, in 100 µL of whole blood we added 20 µL of HLA-DR fluorescein isothiocyanate (FITC) monoclonal antibody and 20 µL of CD64 phycoerythrin (PE) antibody. In another sample of 100 µL of whole blood of the same patient we added 20 µL of isotypic monoclonal antibody marked with FITC and 20 µL of isotypic monoclonal antibody marked with PE, in order to mark our controls. We used as control group 30 diabetic volunteers matched by age and gender. After 30-min incubation period in room temperature, erythrocytes were lysed and leukocytes were fixed with the Multi-Q-Prep system (Coulter, Nyon, Switzerland). At least 10,000 cells from each sample were analyzed on the Epics XL (Coulter) flow cytometer and data were processed with XL2 software. Analysis was performed in a scattergram gate of cells with intermediate side and forward scatter. Results were expressed as percentages of CD64 and HLA-DR positive neutrophils and monocytes, and as arbitrary units (mean fluorescence intensity (MFI)) as well.

The phagocytic activity of neutrophils and monocytes was also measured on the Epics XL (Coulter) flow cytometer, after incubation of 100 µL of whole blood sample with 20 µL of *Escherichia coli* (*E. coli*)-FITC, quenching, lysing and fixation, washing and DNA staining using the Glucotope Phagotest. Results were expressed as percentages of neutrophils and monocytes that appeared on the area marked with the green fluorochrome (FITC).

Statistical analysis {#s2b}
--------------------

All statistical procedures were performed using SPSS 24.0 for Windows (IBM SPSS Statistics, IBM software, IBM Corp., Armonk, NY, USA). Test for normality was done using Kolmogorov-Smirnov test. All variables are expressed as mean ± standard deviation (SD), regardless of their distribution.

Comparison of mean values between subgroups was performed using the independent *t*-test or one-way analysis of variance (ANOVA) when data distribution was normal and Mann-Whitney or Kruskall-Wallis test when the continuous variables were non-normally distributed. When appropriate, the comparisons were adjusted to the effect of additional variables (age, body mass index (BMI), body fat) via the general linear model. Variables that did not follow normal distribution were log-transformed to apply the general linear model. The comparison between diabetics with or without sepsis was controlled for the effect of glycemic control applying two-way ANOVA. Two-tailed statistical significance was set at 5%.

Logistic regression analysis was implemented to assess the association of specific variables with the patient outcome. Correlations with a critical value of P \< 0.05 were considered significant.

Results {#s3}
=======

Of the 51 diabetic patients with sepsis, 40 (78.43 %) survived and 11 (21.56%) died during hospitalization. Five of the non-survivors died within the first 7 days of hospitalization. No special findings in the studied parameters in comparison to those that died later were observed. Three patients were transferred to the intensive care unit, none of whom survived. The etiology of sepsis was respiratory infection (n = 14), urinary tract infection (n = 14), infection of the hepato-biliary tract (n = 8), infection of the skin and soft tissues (n = 12), and osteomyelitis (n = 3) ([Table 1](#T1){ref-type="table"}).

###### Type of Infection

  Infection       Number of patients
  --------------- --------------------
  Respiratory     14 (27.45%)
  Urinary tract   14 (27.45%)
  Osteomyelitis   3 (5.88%)
  Soft tissues    12 (23.52%)
  Abdomen         8 (15.68%)

Only in 19 cases the related causative micro-organism was isolated. The cultures were positive for *E. coli* in eight cases (n = 8), *Klebsiella pneumoniae* (n = 2), *Staphylococcus aureus* (n = 5), *Staphylococcus epidermidis* (n = 2), *Citrobacter* (n = 1) and one patient had poly-microbial infection with *Pseudomonas aeruginosa*, *Klebsiella pneumoniae* and *Proteus mirabilis*, all isolated from rectum abscess.

Statistical analysis showed that diabetic patients with sepsis had higher rates of CD64 expression on monocytes on day 0 and phagocytosis in both monocytes and neutrophils on admission day ([Table 2](#T2){ref-type="table"}).

###### Analysis of Predictors of Mortality Between Survivor and Non-Survivor Diabetics With Sepsis

  Characteristics   Survivors               Non-survivors           P value
  ----------------- ----------------------- ----------------------- ---------
  Age               71.03 ± 12.265          77.55 ± 9.015           0.068
  WBC               15,438.25 ± 7,040.363   13,799.86 ± 6,172.514   0.663
  NLR               9.838 ± 10.8683         12.552 ± 11.0357        0.292
  SAPS II score     30.08 ± 10.159          34.64 ± 10.003          0.136
  CRP               20.640 ± 13.0986        14.990 ± 10.4869        0.304
  HbA1c             8.593 ± 2.6425          7.37 ± 1.17             0.308
  CD64M0            19.38 ± 9.82            15.62 ± 5.22            0.262
  CD64M3            12.88 ± 5.43            10.95 ± 2.83            0.267
  CD64M7            14.40 ± 5.03            9.44 ± 4.42             0.023
  CD64O0            11.58 ± 8.98            9.94 ± 3.99             0.900
  CD64O3            7.83 ± 4.011            6.09 ± 1.49             0.290
  CD64O7            11.03 ± 5.78            6.79 ± 4.24             0.062
  HLA-DRM0          5.59 ± 2.74             5.09 ± 1.89             0.757
  HLA-DRM3          4.54 ± 1.68             4.09 ± 0.96             0.679
  HLA-DRM7          6.60 ± 2.32             4.73 ± 1.39             0.026
  HLA-DRO0          5.23 ± 2.90             4.83 ± 2.16             0.464
  HLA-DRO3          2.93 ± 0.82             3.22 ± 0.94             0.387
  HLA-DRO7          7.19 ± 3.41             5.68 ± 2.91             0.189
  HLA-DR/CD64M0     5.36 ± 2.66             4.85 ± 1.89             0.706
  HLA-DR/CD64M3     4.35 ± 1.62             3.92 ± 0.97             0.747
  HLA-DR/CD64M7     6.49 ± 2.26             4.38 ± 1.31             0.010
  HLA-DR/CD64O0     3.36 ± 1.87             3.36 ± 2.00             0.973
  HLA-DR/CD64O3     2.56 ± 1.42             2.24 ± 0.85             0.245
  HLA-DR/CD64O7     4.21 ± 2.07             2.90 ± 0.82             0.143
  PhagoM0           72.12 ± 19.06           73.99 ± 19.06           0.672
  PhagoM7           70.30 ± 15.96           65.14 ± 23.94           0.709
  PhagoO0           87.85 ± 11.66           88.39 ± 11.25           0.909
  PhagoO7           88.52 ± 10.50           73.38 ± 26.96           0.083

WBC: white blood cells; NLR: neutrophils to lymphocytes ratio; CD64M0: CD64 antigen on monocytes on day 0; CD64M3: CD64 antigen on monocytes on day 3; CD64M7: CD64 antigen on monocytes on day 7; CD64O0: CD64 antigen on neutrophils on day 0; CD64O3: CD64 antigen on neutrophils on day 3; CD64O7: CD64 antigen on neutrophils on day 7; HLA-DRM0: HLA-DR antigen on monocytes on day 0; HLA-DRM3: HLA-DR antigen on monocytes on day 3; HLA-DRM7: HLA-DR antigen on monocytes on day 7; HLA-DRO0: HLA-DR antigen on neutrophils on day 0; HLA-DRO3: HLA-DR antigen on neutrophils on day 3; HLA-DRO7: HLA-DR antigen on neutrophils on day 7; HLA-DR/CD64M0: HLA-DR/CD64 co-expression on monocytes on day 0; HLA-DR/CD64M3: HLA-DR/CD64 co-expression on monocytes on day 3; HLA-DR/CD64M7: HLA-DR/CD64 co-expression on monocytes on day 7; HLA-DR/CD64O0: HLA-DR/CD64 co-expression on neutrophils on day 0; HLA-DR/CD64O3: HLA-DR/CD64 co-expression on neutrophils on day 3; HLA-DR/CD64O7: HLA-DR/CD64 co-expression on neutrophils on day 7; phagoM0: percentage of phagocytosis in monocytes on day 0; phagoM7: percentage of phagocytosis in monocytes on day 7; phagoO0: percentage of phagocytosis in neutrophils on day 0; phagoO7: percentage of phagocytosis in neutrophils on day 7.

When comparing the studied parameters between survivors and non-survivors, the only statistically significant characteristic was the CD64 and HLA-DR expression on monocytes on day 7 after admission, which was elevated in the survivor group (P = 0.023 and P = 0.026).

All results referring to survivors and non-survivors of the group of diabetics with sepsis are shown in [Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}.

###### Analysis of Characteristics in Septic Diabetic Patients With Excellent, Moderate and Inadequate Blood Glucose Control

  Characteristics   HbA1c ≤ 7, HbA1c ≤ 53 mmol/mol   7 \< HbA1c ≤ 8.5, 53 \< HbA1c ≤ 69, 40 mmol/mol   HbA1c \> 8.5, HbA1c \> 69.40 mmol/mol   P value
  ----------------- -------------------------------- ------------------------------------------------- --------------------------------------- ---------
  Age               74 ± 9.13                        74.32 ± 10                                        67.57 ± 16.12                           0.463
  WBC               14,702.86 ± 7,795.94             15,713.64 ± 6294.46                               15,485 ± 6,223.94                       0.983
  NLR               12.16 ± 16.48                    11.19 ± 9.51                                      7.89 ± 4.59                             0.628
  SAPS II score     31.79 ± 10.67                    30.64 ± 8.98                                      31.21 ± 12.43                           0.970
  CRP               18.20 ± 13.50                    16.99 ± 12.08                                     25.92 ± 11.67                           0.130
  HbA1c             6.42 ± 0.51                      7.72 ± 0.38                                       11.25 ± 2.93                            0.000
  CD64M0            22.21 ± 11.88                    18.38 ± 7.98                                      15.71 ± 6.98                            0.270
  CD64M3            12.98 ± 5.60                     12.39 ± 4.85                                      12.20 ± 5.44                            0.775
  CD64M7            13.80 ± 6.16                     13.62 ± 4.69                                      13.62 ± 5.49                            0.860
  CD64O0            14.02 ± 11.85                    12.01 ± 6.85                                      7.59 ± 3.69^a,\ b^                      0.038
  CD64O3            7.18 ± 3.50                      7.96 ± 3.99                                       7.09 ± 3.84                             0.810
  CD64O7            11.53 ± 6.70                     11.01 ± 5.02                                      8.52 ± 5.88                             0.251
  HLA-DRM0          5.89 ± 3.08                      6.09 ± 2.59                                       4.34 ± 1.48                             0.052
  HLA-DRM3          4.56 ± 1.60                      4.87 ± 1.77                                       3.85 ± 1.04                             0.215
  HLA-DRM7          6.80 ± 3.23                      6.17 ± 1.88                                       6.16 ± 2.03                             0.878
  HLA-DRO0          4.93 ± 2.17                      5.85 ± 3.48                                       4.43 ± 1.65                             0.243
  HLA-DRO3          3.45 ± 1.17                      2.87 ± 0.71                                       2.80 ± 0.49                             0.275
  HLA-DRO7          6.15 ± 4.29                      7.54 ± 2.84                                       6.82 ± 3.26                             0.325
  HLA-DR/CD64M0     5.67 ± 3.01                      5.84 ± 2.52                                       4.13 ± 1.39^b^                          0.050
  HLA-DR/CD64M3     4.40 ± 1.57                      4.67 ± 1.69                                       3.66 ± 1.06                             0.193
  HLA-DR/CD64M7     6.52 ± 3.11                      5.95 ± 1.80                                       6.22 ± 2.20                             0.850
  HLA-DR/CD64O0     3.61 ± 1.60                      3.56 ± 2.36                                       2.93 ± 1.21                             0.291
  HLA-DR/CD64O3     2.46 ± 0.82                      2.79 ± 1.85                                       2.16 ± 0.61                             0.383
  HLA-DR/CD64O7     3.91 ± 2.60                      4.09 ± 1.63                                       4.00 ± 2.04                             0.494
  PhagoM0           73.97 ± 19.63                    72.94 ± 15.89                                     69.48 ± 19.23                           0.670
  PhagoM7           74.57 ± 12.38                    69.31 ± 15.90                                     65.55 ± 21.96                           0.671
  PhagoO0           88.72 ± 11.24                    86.76 ± 12.78                                     88.65 ± 10.42                           0.927
  PhagoO7           92.55 ± 4.85                     84.36 ± 12.73                                     83.75 ± 21.29                           0.293

NSGP values: HbA1c ≤ 7, 7 \< HbA1c ≤ 8.5, HbA1c \> 8.5, respectively; IFCC values in mmol/mol: HbA1c ≤ 53, 53 \< HbA1c ≤ 69.40, HbA1c \> 69.40, respectively. NSGP: National Glycohemoglobin Standardization Program; IFCC: The International Federation of Clinical Chemistry and Laboratory Medicine; WBC: white blood cells; NLR: neutrophils to lymphocytes ratio; CD64M0: CD64 antigen on monocytes on day 0; CD64M3: CD64 antigen on monocytes on day 3; CD64M7: CD64 antigen on monocytes on day 7; CD64O0: CD64 antigen on neutrophils on day 0; CD64O3: CD64 antigen on neutrophils on day 3; CD64O7: CD64 antigen on neutrophils on day7; HLA-DRM0: HLA-DR antigen on monocytes on day 0; HLA-DRM3: HLA-DR antigen on monocytes on day3; HLA-DRM7: HLA-DR antigen on monocytes on day 7; HLA-DRO0: HLA-DR antigen on neutrophils on day 0; HLA-DRO3: HLA-DR antigen on neutrophils on day 3; HLA-DRO7: HLA-DR antigen on neutrophils on day7; HLA-DR/CD64M0: HLA-DR/CD64 co-expression on monocytes on day 0; HLA-DR/CD64M3: HLA-DR/CD64 co-expression on monocytes on day 3; HLA-DR/CD64M7: HLA-DR/CD64 co-expression on monocytes on day 7; HLA-DR/CD64O0: HLA-DR/CD64 co-expression on neutrophils on day 0; HLA-DR/CD64O3: HLA-DR/CD64 co-expression on neutrophils on day3; HLA-DR/CD64O7: HLA-DR/CD64 co-expression on neutrophils on day 7; phagoM0: percentage of phagocytosis in monocytes on day 0; phagoM7: percentage of phagocytosis in monocytes on day 7; phagoO0: percentage of phagocytosis in neutrophils on day 0; phagoO7: percentage of phagocytosis in neutrophils on day 7. ^a^P \< 0.05 vs. grI. ^b^P \< 0.05 vs. grII.

###### Analysis of Characteristics Between Septic Patients With Diabetes Mellitus and Diabetic Patients Without Sepsis

  Characteristics   Septic patients with diabetes   Diabetic patients     P value
  ----------------- ------------------------------- --------------------- ---------
  Age               72.43 ± 11.87                   57.88 ± 15.64         0.000
  WBC               15,084.76 ± 6,837.066           7,491.54 ± 2,326.56   0.093
  NLR               10.42 ± 10.85                   2.53 ± 1.30           
  SAPS II score     31.06 ± 10.20                   9.72 ± 5.40           
  CRP               19.38 ± 12.65                                         
  HBA1c             8.34 ± 2.46                     7.75 ± 1.98           0.093
  CD64M0            18.57 ± 9.11                    10.48 ± 2.82          0.000
  CD64M3            12.53 ± 5.08                                          
  CD64M7            13.67 ± 5.21                                          
  CD64O0            11.22 ± 8.16                    8.37 ± 2.53           0.083
  CD64O3            7.51 ± 3.73                                           
  CD64O7            10.40 ± 5.75                                          
  HLA-DRM0          5.48 ± 2.57                     6.86 ± 1.66           0.000
  HLA-DRM3          4.46 ± 1.57                                           
  HLA-DRM7          6.33 ± 2.29                                           
  HLA-DRO0          5.14 ± 2.74                     6.73 ± 8.24           0.666
  HLA-DRO3          2.99 ± 0.84                                           
  HLA-DRO7          6.97 ± 3.35                                           
  HLA-DR/CD64M0     5.25 ± 2.51                     6.61 ± 1.61           0.000
  HLA-DR/CD64M3     4.28 ± 1.52                                           
  HLA-DR/CD64M7     6.18 ± 2.27                                           
  HLA-DR/CD64O0     3.36 ± 1.88                     3.50 ± 4.81           0.000
  HLA-DR/CD64O3     2.50 ± 1.34                                           
  HLA-DR/CD64O7     4.02 ± 1.98                                           
  PhagoM0           72.52 ± 17.58                   46.81 ± 13.14         0.000
  PhagoM7           69.53 ± 17.15                                         
  PhagoO0           87.96 ± 11.46                   74.94 ± 11.67         0.000
  PhagoO7           86.27 ± 14.77                                         

WBC: white blood cells; NLR: neutrophils to lymphocytes ratio; CD64MO: CD64 antigen on monocytes on day 0; CD64M3: CD64 antigen on monocytes on day 3; CD64M7: CD64 antigen on monocytes on day 7; CD64O0: CD64 antigen on neutrophils on day 0; CD64O3: CD64 antigen on neutrophils on day3; CD64O7: CD64 antigen on neutrophils on day7; HLA-DRM0: HLA-DR antigen on monocytes on day 0; HLA-DRM3: HLA-DR antigen on monocytes on day 3; HLA-DRM7: HLADR antigen on monocytes on day7; HLA-DRO0: HLA-DR antigen on neutrophils on day 0; HLA-DRO3: HLA-DR antigen on neutrophils on day 3; HLA-DRO7: HLA-DR antigen on neutrophils on day 7; HLA-DR/CD64M0: HLA-DR/CD64 co-expression on monocytes on day 0; HLA-DR/CD64M3: HLA-DR/CD64 co-expression on monocytes on day 3; HLA-DR/CD64M7: HLA-DR/CD64: co-expression on monocytes on day 7; HLADR/CD64O0: HLA-DR/CD64 co-expression on neutrophils on day 0; HLA-DR/CD64O3: HLA-DR/CD64 co-expression on neutrophils on day 3; HLA-DR/CD64O7: HLA-DR/CD64 co-expression on neutrophils on day 7; phagoM0: percentage of phagocytosis in monocytes on day 0; phagoM7: percentage of phagocytosis in monocytes on day 7; phagoO0: percentage of phagocytosis in neutrophils on day 0; phagoO7: percentage of phagocytosis in neutrophils on day 7.

Discussion {#s4}
==========

Sepsis is now defined as a life-threatening organ dysfunction caused by a dysregulated response of the human to an infection \[[@R07]\]. A number of abnormal immunological responses are generated during the progression of the sepsis syndrome, affecting the production and function of the innate and adaptive immune cells, leading to homeostatic disorders. The sepsis-associated immune defects are associated with increased mortality rates.

DM is one of the most frequent metabolic distortions predisposing for infectious diseases. Rare bacteria, atypical courses and frequent complications of infections are resulting in increased mortality. A number of underlying mechanisms such as the low-grade inflammatory status in DM type 2 (T2DM), the prolonged exposure to glucolipotoxicity and the increased oxidative stress are predisposing to the increased susceptibility to infections. Corner stone is the influence of glycemia on polymorphonuclear cell functions. Contributing factors are altered cellular and humoral immune deficiencies with alterations in neutrophil function and T cell response, poor blood supply to tissues, nerve damage and metabolic alterations \[[@R08]-[@R13]\].

The autoimmune perspectives in T2DM are associated with the presence of auto-antibodies, also including the self-reactive T cells or defects in regulatory T cells (Tregs). One contributor to the autoimmune activation in T2DM seems to be the chronic inflammatory state. Due to this persistent inflammation, tissue destruction leads to the triggering of an autoimmune response of cryptic self antigens, which in turn accelerates β-cell death. An increased secretion of inflammatory cytokines from both innate and adaptive immune system components, specifically macrophages and self-reactive T cells, occurs. However, the extent to which inflammation overlaps with autoimmunity is not known \[[@R14]\].

Neutrophils are the most integral cells of innate function, but in diabetes, they show defects in almost all functions such as migration to inflammatory sites, phagocytosis, release of lytic proteases, production of ROS and apoptosis. They can also eliminate a wide range of microbes by forming neutrophil extracellular traps (NETs). In sepsis, among other dysfunctions there are recognized elevated NET concentrations and these are related to severity of the syndrome and organ dysfunction. The increased tendency of neutrophils to form NETs in both diabetes and sepsis is recognized but how this contributes to worsen outcomes is unknown \[[@R10], [@R15]-[@R18]\].

The main implication on monocytes and to a lesser extent macrophages is reduced antigen presentation related to diminished HLA-DR cell surface expression \[[@R19]\]. In sepsis, an overall immune suppressive monocyte phenotype is well recognized \[[@R20]\]. When a diabetic is exposed to an acute infection, it is not clear enough how monocyte and macrophage populations are changing and how these changes are affected by a baseline obesity and chronic inflammation.

Although DM can massively deteriorate the course of an infection, we should not forget that sepsis as well can be devastating for the control of blood glucose levels. There is a rather bidirectional relationship between those two entities and it would be unfair to solely incriminate diabetes for bad outcomes in a septic patient.

In the present study we sought to evaluate the phagocytic activity of neutrophils and monocytes of diabetic patients suffering from sepsis. We used as markers of this activity the expression of CD64 on monocytes/neutrophils (CD64M/CD64O) and the expression of HLA-DR on monocytes/neutrophils (HLA-DRM/HLA-DRO), in combination with the phagocytic capacity of both populations when exposed to a specific pathogen (*E. coli*).

Flow cytometry showed a decreased expression of CD64M on day 7 since admission, whereas the expression of CD64O was reduced on day 3 but elevated on day 7 of hospitalization. Regarding the expression of HLA-DRM and HLA-DRO, we found a reduction on day 3 of hospitalization, followed by a return to the admission levels regarding monocytes.

The current knowledge regarding pathophysiology of sepsis encompasses a two-stage syndrome with a pro-inflammatory phase lasting from the first 3 to 5 days followed by an anti-inflammatory phase. In our study the expression of both CD64M and CD64O was reduced during the initial phase of sepsis. Similarly, the expression of HLA-DRM and the expression of HLA-DRO are at the lower levels at the early stages.

We also found that the diabetics with sepsis who survived were those with an increased expression of the cell surface markers CD64M, HLA-DRM and HLA-DR/CD64M on day 7, and that was statistically significant with P values of 0.023, 0.026 and 0.010 respectively ([Fig. 1](#F1){ref-type="fig"}). This is related to the underlying immune status of the patients as the increased expression of these markers is associated with higher resistance to infections. With regards to literature, this finding is in accordance with a previous study referring to sepsis population \[[@R21]\].

![Cytometry flow analysis in a control patient (a), a patient with diabetes and sepsis that survived (b), and a patient that deceased (c), showing the expression of HLA-DR and CD64 on monocytes and neutrophils on day 7.](jocmr-12-157-g001){#F1}

We did not find a significant impact of the type of infection, glycemic control, inflammatory markers on admission or the phagocytosis rate on the survival in the hospitalized diabetics who developed sepsis. However, a borderline but no statistically significant association of Simplified Acute Physiology Score (SAPS) II with survival was documented (P = 0.057).

We found a reduced expression of CD64O (P = 0.038), HLA-DRM (P = 0.052) and the co-expression of CD64/HLA-DR on monocytes on admission (P = 0.05) in diabetics with sepsis and poor glycemic control (HbA1c \> 8.5), compared to diabetics with sepsis and good (HbA1c \< 7) or moderate glycemic control (7 \< HbA1c \< 8.5). These findings are consistent with the increased susceptibility of diabetics to infections especially in the cases with poor glycemic control. No association between glycemic control and phagocytosis rates was identified, as in the study by Lin where it was shown that poor glycemic control plays a role in impairing neutrophil phagocytosis of capsular serotypes K1/K2 *Klebsiella pneumoniae* \[[@R22]\].

Although this is a study with a relatively small sample size, some useful information can be extracted with regards to the immunologic reaction of diabetics who suffered from sepsis. In this case series a prognostic relation was found between the studied markers CD64 and HLA-DR of monocytes and survival, whereas no relation between type of infection, glycemic control and the outcome was found. Especially, with regards to antigenic expression although this was reduced in both neutrophils and monocytes during the first days of infection, no statistical significance with outcome was noticed. Also, the present study failed to document a relationship between the type of infection with inflammatory markers on admission and the expression of cell surface markers (CD64, HLA-DR, co-expression CD64/HLA-DR, and rate of phagocytosis in neutrophils (phagoO) and phagocytosis in monocytes (phagoM)). There are many tools in the assessment of the complex underlying pathophysiology in sepsis nowadays including the assessment of the complement pathway and the cytokine profile which could be proved more useful also as prognostic factors. Towards this direction, perhaps the study of other parameters such as complement and cytokine profile could prove to be more useful as prognostic factors. Complement 3 receptor expression has been recorded to be reduced in diabetics with type 2 diabetes compared to non-diabetics \[[@R23]\], and also the role of cytokines in T1DM and T2DM is investigated \[[@R24]\].

Conclusions {#s4a}
-----------

The combination of the immune alterations in diabetes with the immune dysregulation during the process of the sepsis syndrome offers a field of interest for tailored interventions. A research effort now is focused on the interplay between sepsis, diabetes and immunity and their impact on survival. This is a small case series indicating alterations of neutrophils and monocytes in diabetics suffering from sepsis at least in the initial phase of acute infection. Large prospective studies are needed to investigate the immune alterations of high risk for population of diabetics who develop sepsis.
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